Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Genbase Biotechnology Co LtdfiledCriticalShanghai Genbase Biotechnology Co Ltd
Priority to CL2021001021ApriorityCriticalpatent/CL2021001021A1/en
Publication of CL2021001021A1publicationCriticalpatent/CL2021001021A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente invención se refiere al campo de la inmunología y al tratamiento de enfermedades. En particular, la presente invención se refiere a un anticuerpo anti-CLDN18.2 o fragmento de unión a antígeno del mismo, una molécula de ácido nucleico que lo codifica, un inmunoconjugado, una molécula biespecífica, un receptor de antígeno quimérico y una composición farmacéutica que lo comprende, y los usos del mismo para la prevención y/o tratamiento de un tumor.The present invention relates to the field of immunology and the treatment of diseases. In particular, the present invention relates to an anti-CLDN18.2 antibody or antigen-binding fragment thereof, a nucleic acid molecule encoding it, an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, and a pharmaceutical composition. comprising it, and the uses thereof for the prevention and / or treatment of a tumor.
CL2021001021A2021-04-212021-04-21
Anti-cldn18.2 antibody and its uses.
CL2021001021A1
(en)
Labeled antibody and / or fragment thereof comprising a monoclonal antibody or a fragment thereof, which specifically binds human tau; nucleic acid that encodes it; vector; cell; method of producing antibody; and use of the same to inhibit the aggregation of tau, and associated diseases (divisional application no. 202001003)
antibody or antigen binding fragment thereof, combination of isolated nucleic acid molecules, pharmaceutical composition, kit, and method for selecting a compound.